Document is current
Any future updates will be listed below
-
Authors
Hintelmann, Katharina https://orcid.org/0009-0007-0438-7942
Wahaj, Schohla
Henze, Marvin
Laakmann, Elena
Müller, Volkmar
Krug, David
Gauer, Tobias
Petersen, Cordula
-
Funding
Funding for this research was provided by:
Hamburger Krebsgesellschaft
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 8 October 2024
Accepted: 26 January 2025
First Online: 7 March 2025
Declarations
:
: K. Hintelmann, S. Wahaj, M. Henze, T. Gauer and C. Petersen declare that they have no competing interests. E. Laakmann reports travel expenses from Pierre Fabre, honoraria for educational events from Astra Zeneca, Seagen and advisory board fees from Novartis, Astra Zeneca and Daiichi Sankyo (all outside this manuscript). V. Müller Speaker honoraria: Astra Zeneca, arsTempi, Daiichi-Sankyo, Eisai, Pfizer, MSD, Medac, Novartis, Roche, Seagen, Onkowissen, high5 Oncology, Lilly, Medscape, Gilead, Pierre Fabre, iMED Institut. Consultancy honoraria: Roche, Pierre Fabre, PINK, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Seagen, Gilead, Stemline. Institutional research support: Novartis, Roche, Seagen, Genentech, Astra Zeneca.Travel grants: Astra Zeneca, Roche, Pfizer, Daiichi Sankyo, Gilead. D. Krug has received honoraria from Astra Zeneca, best practice onkologie, ESO, ESMO, Gilead, med update, Merck Sharp & Dohme, Novartis, onkowissen, and Pfizer, as well as research funding from Stiftung Deutsche Krebshilfe and Merck KGaA.
: Ethical approval was waived by the local Ethics Committee of University Hospital Hamburg-Eppendorf in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.
